Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,743 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Diabetes Mellitus, Type 2, Vascular Diseases
Interventions: Rosiglitazone, Pioglitazone; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 40 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Sodium Excess, Racial Disparities, Blood Pressure, Cardiovascular Risk Factor
Interventions: Low Sodium Meal (140 mg sodium chloride), High Sodium Meal (2500 mg sodium chloride); Other
Lead sponsor: Indiana University; Other
Eligibility: 19 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Auburn, Alabama • Bloomington, Indiana

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cardiovascular Disease
Interventions: discharge vs. overnight stay; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Metabolic Syndrome
Interventions: Blueberry Powder; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Type 1 Diabetes, Obesity
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Viral N. Shah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Aurora, Colorado • West Des Moines, Iowa • Detroit, Michigan + 1 more

Conditions: Plaque, Atherosclerotic, Carotid Artery Plaque, Carotid Stenosis
Interventions: Acoustic Radiation Force Impulse (ARFI) ultrasound; Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Myocardial Infarction
Interventions: CalmioGO Stress management device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions: Chlorthalidone, Lisinopril, Amlodipine, Doxazosin; Drug
Lead sponsor: Donna Arnett, 257-5678; Other
Eligibility: 55 Years and older
Enrollment: 37,939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Atrial Fibrillation, Heart Failure
Interventions: Reveal XT® Insertable Cardiac Monitor, Heart Failure Risk Status Diagnostic; Device · Other
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: La Jolla, California • Aurora, Colorado • Grand Rapids, Michigan + 8 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older
Enrollment: 8,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 121
States / cities: Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more

Conditions: Dyslipidemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 27,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 326
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more

Conditions: High Risk Atherosclerotic Cardiovascular Disease
Interventions: Electronic Alert; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 2,596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Bridgeport, Connecticut • Greenwich, Connecticut • New Haven, Connecticut

Conditions: Hypertriglyceridemia (TG>200<500), Hyperlipidemia, Coronary Artery Disease, Coronary Risk Equivalent, Diabetes
Interventions: docosahexanoic acid (DHA); Drug
Lead sponsor: Maine Center for Lipids and Cardiovascular Health; Other
Eligibility: 21 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Scarborough, Maine

Conditions: Cardiovascular Risk Factor
Interventions: xylitol, 30g, erythritol, 30g, xylitol, 5g, glucose, 30g; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Weight Loss, Men, Lifestyle Risk Reduction, Cardiovascular Diseases, Obesity
Interventions: Self-guided lifestyle intervention; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Multiple Myeloma
Interventions: CART-19 cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiovascular Disease, Peripheral Artery Disease, Ischemic Stroke, Diabetes
Interventions: Web-Based Intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stable Coronary Artery Disease (CAD), Myocardial Infarction
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years and older
Enrollment: 9,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 34
States / cities: Huntsville, Alabama • Los Angeles, California • Santa Ana, California + 31 more

Conditions: Myocardial Infarction
Interventions: Not listed
Lead sponsor: University of Vermont; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Diabetes, Hypertension, Dyslipidemia, Coronary Arteriosclerosis
Interventions: Behavioral counseling and peer support, Interactive Education, Role modeling, Pharmacologic case management; Behavioral · Procedure
Lead sponsor: Providence VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions: Glutathione, N-Acetylcysteine, Placebo; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Nicotine Dependance, Serious Mental Illness, Smoking (Tobacco) Addiction, Tobacco Cessation, Community Health Workers, Cardiovascular (CV) Risk, Tobacco Use Disorder
Interventions: Integrated CHW Support intervention, Enhanced usual care (EUC); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: High Cardiovascular Risk, Hypertension
Interventions: Zilebesiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 139
States / cities: Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more

Search by objective public record fields.

Effect of Thiazolidinedione Treatment Vascular Risk Markers

Vascular Effects of Acute Sodium (VEAS) Study

The Learning Registry

Same Day Versus Next Day Discharge: Ambulatory Closure Device Percutaneous Intervention

The Effect of Blueberry Powder Supplementation on Cardiovascular Risk Factors in Subjects With the Metabolic Syndrome

ADJUnct Semaglutide Treatment in Type 1 Diabetes

Transcutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk

Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.

Genetics of Hypertension Associated Treatments (GenHAT)

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)

The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes

Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion

A Novel Approach to Reducing Adiposity Among Young Men

CART-19 Post-ASCT for Multiple Myeloma

Personalized Cardiovascular Risk Information to Initiate and Maintain Health Behavior Changes

Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients

Novel Biomarkers of Thrombotic Risk

Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

Evaluation of Community Health Worker Support to Help People With Serious Mental Illness to Quit Smoking

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)